An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer.
Jean-Louis PujolAmandine CoffyAndrea CameriniAthanasios KotsakisManlio MencoboniMilena GusellaFelice PasiniAldo PezzutoGiuseppe Luigi BannaCemil BilirEpaminontas SamantasFabrice BarlesiBenoit RochAude GuillouJean-Pierre DaurèsPublished in: PloS one (2019)
MOV is an active and well-tolerated chemotherapy in metastatic NSCLC and is a manageable therapy in frail patients.
Keyphrases
- small cell lung cancer
- systematic review
- end stage renal disease
- squamous cell carcinoma
- newly diagnosed
- ejection fraction
- chronic kidney disease
- case report
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- stem cells
- advanced non small cell lung cancer
- machine learning
- artificial intelligence
- epidermal growth factor receptor
- community dwelling
- chemotherapy induced